Aptar scoops up two pharma services firms in $50m deal

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags: Aptar Group, Analytical testing, Drug development

Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.

Headquartered in Crystal Lake, IL, Aptar​ provides a range of dispensing, sealing, and active packaging solutions and this week purchased the two companies for a combined enterprise value of approximately $50m.

Nanopharm provides analytical and drug development services with a focus on orally inhaled and nasal drug products and is located in Newport, UK, while Gibsonia, PA-based Gateway Analytical provides particulate detection and predictive analytical services to customers developing injectable medicines.

According to Aptar, the acquisitions are in line with the company’s strategy to expand its services portfolio.

The addition will enable the company to collaborate with customers earlier, supporting drug formulation and delivery.

Aptar has previously voiced plans to expand globally​ as part of a multi-year investment plan in response to expected growth in the injectable market driven by biologics and vaccines.

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars